CA3233866A1 - Treatment of kidney disease - Google Patents
Treatment of kidney disease Download PDFInfo
- Publication number
- CA3233866A1 CA3233866A1 CA3233866A CA3233866A CA3233866A1 CA 3233866 A1 CA3233866 A1 CA 3233866A1 CA 3233866 A CA3233866 A CA 3233866A CA 3233866 A CA3233866 A CA 3233866A CA 3233866 A1 CA3233866 A1 CA 3233866A1
- Authority
- CA
- Canada
- Prior art keywords
- patient
- egfr
- approximately
- kidney
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/22—Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0684—Cells of the urinary tract or kidneys
- C12N5/0686—Kidney cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Developmental Biology & Embryology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Dermatology (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163255885P | 2021-10-14 | 2021-10-14 | |
| US63/255,885 | 2021-10-14 | ||
| US202263307801P | 2022-02-08 | 2022-02-08 | |
| US63/307,801 | 2022-02-08 | ||
| US202263321204P | 2022-03-18 | 2022-03-18 | |
| US63/321,204 | 2022-03-18 | ||
| PCT/US2022/078153 WO2023064925A1 (en) | 2021-10-14 | 2022-10-14 | Treatment of kidney disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3233866A1 true CA3233866A1 (en) | 2023-04-20 |
Family
ID=85988933
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3233866A Pending CA3233866A1 (en) | 2021-10-14 | 2022-10-14 | Treatment of kidney disease |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250009803A1 (https=) |
| EP (1) | EP4415729A4 (https=) |
| JP (1) | JP2024536479A (https=) |
| KR (1) | KR20240110801A (https=) |
| AU (1) | AU2022362077A1 (https=) |
| CA (1) | CA3233866A1 (https=) |
| MX (1) | MX2024004355A (https=) |
| WO (1) | WO2023064925A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025106530A1 (en) * | 2023-11-13 | 2025-05-22 | Butler Emily | Characteristics of enriched heterogeneous renal cell populations |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020266168A1 (en) * | 2019-05-02 | 2021-12-02 | ProKidney IPCo, LLC | Treatment of kidney disease in subjects with kidney and/or urinary tract anomalies |
-
2022
- 2022-10-14 AU AU2022362077A patent/AU2022362077A1/en active Pending
- 2022-10-14 US US18/699,849 patent/US20250009803A1/en active Pending
- 2022-10-14 CA CA3233866A patent/CA3233866A1/en active Pending
- 2022-10-14 JP JP2024522027A patent/JP2024536479A/ja active Pending
- 2022-10-14 KR KR1020247015819A patent/KR20240110801A/ko active Pending
- 2022-10-14 MX MX2024004355A patent/MX2024004355A/es unknown
- 2022-10-14 WO PCT/US2022/078153 patent/WO2023064925A1/en not_active Ceased
- 2022-10-14 EP EP22882059.3A patent/EP4415729A4/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023064925A1 (en) | 2023-04-20 |
| US20250009803A1 (en) | 2025-01-09 |
| JP2024536479A (ja) | 2024-10-04 |
| KR20240110801A (ko) | 2024-07-16 |
| EP4415729A4 (en) | 2025-08-27 |
| WO2023064925A8 (en) | 2024-04-11 |
| AU2022362077A1 (en) | 2024-05-02 |
| EP4415729A1 (en) | 2024-08-21 |
| MX2024004355A (es) | 2024-06-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Skyler et al. | Allogeneic mesenchymal precursor cells in type 2 diabetes: a randomized, placebo-controlled, dose-escalation safety and tolerability pilot study | |
| Ulus et al. | Intramyocardial transplantation of umbilical cord mesenchymal stromal cells in chronic ischemic cardiomyopathy: a controlled, randomized clinical trial (HUC-HEART Trial) | |
| Crisostomo et al. | Dose-dependent improvement of cardiac function in a swine model of acute myocardial infarction after intracoronary administration of allogeneic heart-derived cells | |
| US20140335058A1 (en) | Assay for the prediction of therapeutic effectiveness of mesenchymal stromal cells, and methods of using same | |
| EP4181935A1 (en) | Methods and compositions for treating lung conditions | |
| US20250288616A1 (en) | Bioactive renal cells for the treatment of chronic kidney disease | |
| Khalili et al. | Treatment for salivary gland hypofunction at both initial and advanced stages of Sjögren-like disease: a comparative study of bone marrow therapy versus spleen cell therapy with a 1-year monitoring period | |
| US20100111908A1 (en) | Induction of Renal Cells for Treatment of Kidney Disease | |
| US20250009803A1 (en) | Treatment of kidney disease | |
| US20070172447A1 (en) | Agent for preventing and/or treating tissue disruption-accompanied diseases | |
| Stavas et al. | Renal autologous cell therapy to stabilize function in diabetes-related chronic kidney disease: corroboration of mechanistic action with cell marker analysis | |
| Scott-Emuakpor et al. | Role of oral retinoids in treatment of acne vulgaris with a bioinformatics-based perspective of personalized medicine | |
| CN118354777A (zh) | 肾脏疾病的治疗 | |
| HK40113884A (zh) | 肾脏疾病的治疗 | |
| Schmid et al. | New strategies for managing anemia of chronic kidney disease | |
| MARYNIAK et al. | RECURRENCE OF DIABETIC NODULAR: GLOMERULOSCLEROSIS IN A RENAL TRANSPLANT | |
| KR20240034745A (ko) | 동물의 골관절염 치료용 중간엽 줄기세포 | |
| US20240299328A1 (en) | Compositions comprising 15-hepe and methods of treating and/or preventing hematologic disorders and related diseases | |
| DiCarlo et al. | Acute kidney injury in pediatric stem cell transplant recipients | |
| CN114350607B (zh) | 骨髓来源的成熟b细胞及其在制备治疗心肌梗死的药物中的应用 | |
| TWI780431B (zh) | 新穎性醫藥組合物及其於修復肝臟損傷、治療肝臟損傷相關疾病與提升肝臟功能之用途 | |
| Gariani et al. | Impact of Islet Transplantation on Type 1 Diabetes-Related Complication: A Systematic Review | |
| RU2833560C1 (ru) | Композиции, содержащие 15-hepe, для лечения или профилактики гематологических нарушений и/или связанных заболеваний | |
| Raafat et al. | SGLT2 Inhibitors and Myocardial Infarction in Diabetes: Current Insights into Cardioprotective Mechanisms | |
| US20230094263A1 (en) | Methods For Treating Coronavirus Disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240904 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240904 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240904 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251010 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251010 |